Cerulea Clinical Trials

Clinical Trials

ADVISE

Adalimumab vs. Conventional Immunosuppression for Corticosteroid-sparing for Uveitis Trial

Overview

The ADVISE Trial is a randomised, parallel-treatment, comparative effectiveness trial.

It aims to compare the relative effectiveness of adalimumab compared to conventional immunosuppression at controlling ocular inflammation caused by uveitis, while permitting tapering and discontinuation of oral corticosteroids.

  • Principal Investigator
Professor Lyndell Lim

Learn more

View this study at ClinicalTrials.gov

This international database listing provides more detailed information about this study.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.